FarmavitaR+

1. Pharmaceutical Pricing & Reimbursement in Turkey
(Events/Events)

Pharmaceutical Pricing & Reimbursement in Turkey   Penetrating and optimising market access techniques in a complex and high growth-potential market   22nd September, 2010, Istanbul, Turkey ...

2. Pricing and Reimbursement Strategies
(Reports/Market Report)

... by the CMS in the reimbursement amount for non-facility units is expected to impact the diagnostic devices market especially in the form of lack of innovation. The reimbursement structure is restraining ...

3. Clinical Trials 2010
(Events/Events)

... a clinical strategy to successfully COMPETE FOR THE FUTURE and bring commercially viable drugs to market faster.    Empower yourself with the knowledge. These industry leaders will share how they ...

4. Ukraine in prospect of joining PIC/S
(Regulatory Affairs/Europe not-EU)

... to implement European standards in the drug market and the harmonization of Ukrainian legislation with international norms. The Committee of PIC / S are 2 times a year. Last held 19-20 May 2010 in Geneva, ...

5. Achieving preferential patient-access through innovative agreements with payers
(Events/Events)

... market access. Why Attend? Discover if successful agreements from European and other markets, can be implemented in the USA.  Understand the opportunities, obstacles and challenges in designing ...

6. Long-term pricing & reimbursement strategies to penetrate significant growth markets
(Events/Events)

2nd Annual Pharmaceutical Market & Patient Access for Chronic Disease Therapies 15th-16th September, 2010 Brussels, Belgium Chronic diseases are taking a steadily increasing share of national ...

7. Evolution Summit 2010
(Events/Events)

... profit margins. Infusing the pipeline with talented manpower and reliable risk containment techniques leads the pharmaceutical industry into a new age of productivity. In the competitive drug market, ...

8. Fibromyalgia
(Regulatory Affairs/Regulatory Affairs News)

Fibromyalgia - Regulatory caution threatens EU market expansion Until regulatory hurdles in the EU are overcome, the US offers the greatest commercial potential and will be the primary growth market ...

9. Pricing and Reimbursement Conference Review
(Pricing and Reimbursment/Pricing and Reimbursment)

... for Croatia. In Italy they developed conditional reimbursment models in combination with post-marketing evaluation of product via Register of new drugs. This concept is specially interesting for high-value ...

10. Patern Ltd.
(Partners/Regulatory Affairs)

Patern Ltd. was established in 1998 and reorganized in 2005 as a medical market entry company. Our main line of activity is outsourcing services for manufacturers, representative offices and distributors ...

11. Patern Ltd.
(Partners/Regulatory Affairs)

Patern Ltd. was established in 1998 as a medical market entry company. The main line of activity is outsourcing services for manufacturers, representative offices and distributors of the pharmaceutical ...

12. Emerging Biosimilars Landscape
(Reports/Market Report)

... biosimilar market. It also provides a comprehensive review of the current legislative and regulatory positions of key geographic regions in addition to evaluating their anticipated future legislative changes ...

13. Emerging Clinical Trial Locations
(Clinical Trilas/Europe not-EU)

Emerging Clinical Trial Locations: Market dynamics and the changing healthcare and regulatory environment This report provides a comprehensive examination of the clinical trial landscape in emerging ...

14. Biosimilars: Key developments in the regulatory environment
(Reports/Product Report)

... opportunities have been created for generics companies in the biopharmaceutical market, which according to IMS data was valued at $85.9 billion in 2007. Conservative projections estimate that sales of ...

15. The Top 10 Biosimilar Players
(Reports/Market Report)

The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses Biologics continue to outperform the global pharma market, driven by premium priced therapies for conditions that cannot be managed ...

16. New Approaches to Pharma R&D
(Reports/Market Report)

... shift towards niche markets and personalized medicines. The number of pipeline deals made during 2006/08 have steadily declined. However, with Biotech finding it hard to fund R&D at present, and with ...

17. Clinical Trial in India
(Clinical Trilas/Asia)

... have become a hot spot for clinical research, one needs to look at the drug development process in totality. This process, which starts in the research labs and ends with a drug being launched in the market, ...

18. Standardization of Herbal Drugs
(Professional Articles/Life Science Article)

... and this demand is increasing everyday in the world market. It is well known that traditional herbal medicines existed before the application of the modern scientific methods to health care (Subramoniam, ...

19. Act on Medical Products and Medical Devices
(Regulatory Affairs/Europe not-EU)

...  Only the products with approval from the Agency can be placed on the market in Bosnia and Herzegovina. The law is available for download at Downloads section of Farmavitar.Net. (in Bosnian!)  ...

20. Variations
(Regulatory Affairs/Europe not-EU)

... marketing authorisation. The whole 10 pages article is available for download at Downloads section of Farmavitar.Net In the Annex 1 one can find a from "APPLICATION FOR REGISTRATION OF VARIATIONS". ...